Ligand Pharmaceuticals Inc

Chart & Performance

D1W1MN

P/E

0.00

P/S

0.00

EPS

2.76

Div Yield, %

0.00%

Shrs. gr., 5y

-5.90%

Rev. gr., 5y

-12.18%

Revenues

131m

-33.09%

Net income

52m

CFO

50m

-64.04%

Earnings

Feb 25, 2025

Profile

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.

URL

https://www.ligand.com/

IPO date

Nov 18, 1992

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title USD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title USD in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12	2014‑12
Income
Revenues	131,314 -33.09%	196,245 -29.19%	277,133 48.66%
Cost of revenue	112,376	158,971	188,671
Unusual Expense (Income)
NOPBT	18,938	37,274	88,462
NOPBT Margin	14.42%	18.99%	31.92%
Operating Taxes	9,841	41,230	(10,288)
Tax Rate	51.96%	110.61%
NOPAT	9,097	(3,956)	98,750
Net income	52,154 -1,099.31%	(5,219) -109.13%	57,138 -2,014.17%
Dividends
Dividend yield
Proceeds from repurchase of equity	17,901	(5,004)	15,317
BB yield	-1.41%	0.44%	-0.58%
Debt
Debt current	410	77,410	46
Long-term debt	11,920	21,387	351,751
Deferred revenue	1,444	30,615
Other long-term liabilities	62,322	(5,193)	39,459
Net debt	(206,300)	(116,073)	10,689
Cash flow
Cash from operating activities	49,577	137,850	78,798
CAPEX	(3,521)	(17,923)	(8,761)
Cash from investing activities	(11,682)	163,624	30,523
Cash from financing activities	(59,947)	(275,990)	(137,761)
FCF	(21,373)	65,477	6,711
Balance
Cash	170,309	211,870	341,108
Long term investments	48,321	3,000
Excess cash	212,064	205,058	327,251
Stockholders' equity	502,217	450	448,190
Invested Capital	558,780	710,203	870,094
ROIC	1.43%		11.73%
ROCE	2.46%	5.03%	7.02%
EV
Common stock shares outstanding	17,757	16,868	17,246
Price	71.42 6.92%	66.80 -56.75%	154.46 55.31%
Market cap	1,268,205 12.55%	1,126,782 -57.70%	2,663,817 65.50%
EV	1,061,905	1,010,709	2,674,506
EBITDA	54,581	88,644	139,408
EV/EBITDA	19.46	11.40	19.18
Interest	656	1,799	18,740
Interest/NOPBT	3.46%	4.83%	21.18%